Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer
Authors:
Open Access
- 1 October 2021
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 39 (10) , 728.e13-728.e24
Abstract
No abstract availableKeywords
Funding Information
- Ministry for Innovation and Technology (NKFIH/FK_12443, NVKP_16-1-2016-004, ÚNKP-20-3-II-SE-8)
- National Research, Development and Innovation Office (NKFIH/FK_12443, NVKP_16-1-2016-004, ÚNKP-20-3-II-SE-8)
- Magyar Tudományos Akadémia (NKFIH/FK_12443, NVKP_16-1-2016-004, ÚNKP-20-3-II-SE-8)
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (NKFIH/FK_12443, NVKP_16-1-2016-004, ÚNKP-20-3-II-SE-8)
This publication has 51 references indexed in Scilit:
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Androgen receptor: structure, role in prostate cancer and drug discoveryActa Pharmacologica Sinica, 2014
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor BlockadeCell, 2013
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)Cancer Discovery, 2013
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Cancer Discovery, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate CancerCancer Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011